BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:With investment into the Treg field at an all time high\, exci
 tement is overflowing at the prospect of these remarkable cells being gam
 e-changers in the long-term treatment of autoimmunity\, inflammation and 
 transplantation. As this enthusiasm coincides with multiple clinical read
 outs and several more therapies entering the clinic\, it remains vital fo
 r Treg trailblazers to come together to recognize therapy efficacy\, dete
 rmine safety and translate the next-generation of therapies into the clin
 ic. &nbsp\;\n\nThe Treg Summit returns for the 5th year to unite this ded
 icated community of industry and academic experts\, and remains the go-to
  industry forum to advance both cell and non-cell based approaches to unl
 ock the potential of Tregs to treat indications with huge unmet clinical 
 need.&nbsp\;\n\nWith 3 jam-packed days of content across CAR-\, TCR- and 
 polyclonal Tregs as well as IL-2\, muteins and small molecules\, you won'
 t want to miss this unrivalled opportunity to collaborate with your peers
  in the Treg field to explore clinical advances\, discuss challenges and 
 discover next-gen methods to take Treg therapies to the next level.&nbsp\
 ;\n\nURLs:Tickets:&nbsp\;https://go.evvnt.com/1558199-2?pid=185Brochure:&
 nbsp\;https://go.evvnt.com/1558199-3?pid=185\n\nPrices:Drug Developer - C
 onference + Bootcamp Day: USD 4946.00\,Drug Developer - Conference Only: 
 USD 2999.00\,Academic - Conference + Bootcamp Day: USD 4246.00\,Academic 
 - Conference Only: USD 2599.00\,Standard - Conference + Bootcamp Day: USD
  6046.00\,Standard - Conference Only: USD 3799.00\n\nSpeakers:&nbsp\;Ali 
 Zarrin\, Vice President and Head of Discovery\, TrexBio\, Alison Budelsky
 \, Head of Immunology Discovery\, Eli Lilly\, Anish Suri\, President and 
 Chief Scientific Officer\, Cue Biopharma\, Bertolt Kreft\, Chief Scientif
 ic Officer\, Bright Peak Therapeutics\, Dan Mandell\, Chief Executive Off
 icer and Co-Founder\, GRO Biosciences\, David Klatzmann\, Professor\, Sor
 bonne University\, David Zemmour\, Assistant Professor of Pathology\, Zem
 mour Lab\, University of Chicago\, Denise Faustman\, Associate Professor\
 , Harvard Medical School\, Diane Mathis\, Professor of Immunology\, Harva
 rd Medical School\, Dirk Brockstedt\, Chief Scientific Officer\, RAPT The
 rapeutics\, Eliane Piaggio\, Scientific Co-founder and Chief Scientific O
 fficer\, Egle Therapeutics\, Ethan Shevach\, Chief\, Cellular Immunology 
 Section\, NIH/NIAID\, Fanny Chapelin\, Assistant Professor\, Department o
 f Biomedical Engineering\, University of Kentucky\, Haining Huang\, Chief
  Scientific Officer\, Sorrento Therapeutics Inc.\, Heth Turnquist\, Assoc
 iate Professor\, University of Pittsburgh School of Medicine\, Hye-Jung K
 im\, Distinguished Scientist\, Genentech\, James Mathew\, Professor\, Nor
 thwestern University Feinberg School of Medicine\, Jeff Bluestone\, Chief
  Executive Officer and President\, Sonoma Biotherapeutics\, Jennifer Town
 e\, Vice President\, Immunology Discovery and External Innovation\, Janss
 en\, Kei Kishimoto\, Chief Scientific Officer\, Selecta Biosciences\, Leo
 nard Dragone\, Chief Medical Officer\, Sonoma Biotherapeutics\, Marc Mart
 inez-Llordella\, Co-founder and Vice President\, Biology\, Quell Therapeu
 tics\, Melanie Kleinschek\, Chief Scientific Officer\, TrexBio\, Michelle
  Higgin\, Chief Operating Officer\, Slate Bio\, Mojca Skoberne\, Entrepre
 neur In Residence\, GV\, Niranjana Nagarajan\, Vice President - Research\
 , Abata Therapeutics\, Piotr Trzonkowski\, Chief Executive Officer\, Polt
 reg\, Rahul Sharma\, Chief Scientific Officer\, Slate Bio\, Raphael Clyne
 s\, Vice President - Translational Biology\, Xencor\, Roly Foulkes Chief 
 Scientific Officer\, Revolo Biotherapeutics\, Tom Wickham\, Chief Scienti
 fic Officer\, GentiBio\, Tracey Lodie\, Chief Scientific Officer\, Quell 
 Therapeutics\, Uli Bialucha\, Chief Scientific Officer\, Xilio Therapeuti
 cs\, Zohreh Amoozgar\, Principal Scientist and Head of Lab\, Sanofi\n\nTi
 me:&nbsp\;9:30 am to 4:30 pm\n
DTEND:20230601T163000
DTSTAMP:20260512T234653Z
DTSTART:20230530T093000
LOCATION:Hyatt Regency Boston\, 1\, Avenue de Lafayette\, Boston\, Suffolk
  County\, 02111\,
SEQUENCE:0
SUMMARY:With investment into the Treg field at an all time high\, exciteme
 nt is overflowing at the prospect of these remarkable cells being game-ch
 angers in...
UID:79ba7412-3dee-4596-b59d-d7ea2a3ab91c
END:VEVENT
END:VCALENDAR